Imatinib for chronic myeloid leukaemia: a NICE mess.
作者信息
Barbour V
机构信息
The Lancet, WC1X 8RR, London, UK.
出版信息
Lancet. 2001 Nov 3;358(9292):1478. doi: 10.1016/S0140-6736(01)06571-0.
Abstract
摘要
相似文献
1
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Nov 3;358(9292):1478. doi: 10.1016/S0140-6736(01)06571-0.
2
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Dec 1;358(9296):1902. doi: 10.1016/S0140-6736(01)06901-X.
3
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Dec 1;358(9296):1902-3. doi: 10.1016/s0140-6736(01)06902-1.
4
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Dec 1;358(9296):1903. doi: 10.1016/S0140-6736(01)06903-3.
5
Position paper on imatinib mesylate in chronic myeloid leukaemia.
Br J Haematol. 2002 Oct;119(1):268-72. doi: 10.1046/j.1365-2141.2002.39201.x.
6
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Health Technol Assess. 2002;6(33):1-162. doi: 10.3310/hta6330.
7
NICE backs leukaemia drug after manufacturer drops price.
BMJ. 2012 Mar 22;344:e2274. doi: 10.1136/bmj.e2274.
8
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.
9
10
Chronic myelogenous leukemia.
Am J Manag Care. 2012 May;18(3 Spec No.):SP105-7.
Zotero 插件